GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) » Definitions » PB Ratio

Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) PB Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-29), Santhera Pharmaceuticals Holding AG's share price is $11.70. Santhera Pharmaceuticals Holding AG's Book Value per Share for the quarter that ended in Jun. 2023 was $-5.17. Hence, Santhera Pharmaceuticals Holding AG's PB Ratio of today is .

The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's PB Ratio or its related term are showing as below:

During the past 13 years, Santhera Pharmaceuticals Holding AG's highest PB Ratio was 57.09. The lowest was 0.50. And the median was 4.73.

SPHDF's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.375
* Ranked among companies with meaningful PB Ratio only.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Santhera Pharmaceuticals Holding AG was 86.30% per year. The lowest was -78.30% per year. And the median was -30.00% per year.

Back to Basics: PB Ratio


Santhera Pharmaceuticals Holding AG PB Ratio Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG PB Ratio Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.28 6.30 - 48.45 -

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.71 48.45 - - -

Competitive Comparison of Santhera Pharmaceuticals Holding AG's PB Ratio

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's PB Ratio distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's PB Ratio falls into.



Santhera Pharmaceuticals Holding AG PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Santhera Pharmaceuticals Holding AG's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2023)
=11.70/-5.165
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Santhera Pharmaceuticals Holding AG PB Ratio Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.